Bremelanotide (PT-141) is a synthetic cyclic heptapeptide from the class of melanocortin receptor agonists. Its structure is usually written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The molecule is related to melanotan II (MT-II) and is essentially its active metabolite, with weakened pigmentary ("tanning") activity but retained action on the central neural pathways tied to sexual desire [5][6]. Unlike phosphodiesterase-5 inhibitors, which work mainly through a vascular mechanism, bremelanotide acts "from the top", at the level of the central nervous system [4][6].
What it is and its class
The melanocortin system is a family of receptors (MC1R through MC5R) and their peptide ligands that regulate pigmentation, inflammation, energy metabolism and, as preclinical and clinical work has shown, certain aspects of sexual behavior. Bremelanotide is a non-selective agonist of several subtypes, but the receptor considered key to its effect on sexual desire is MC4R, widely present in the hypothalamus and other brain regions [5][8]. It is the central rather than peripheral action that sets this peptide apart from most other agents studied in sexual disorders [4].
Mechanism of action
According to available data, activation of melanocortin receptors (chiefly MC4R) in brain regions involved in the regulation of motivation and arousal, particularly the medial preoptic area of the hypothalamus, modulates dopaminergic pathways linked to sexual desire [4][5]. The effect therefore plays out at the level of neural regulation of desire, not through a direct influence on tissue blood flow. This is a fundamental difference from vascular-acting drugs and the reason bremelanotide was studied first of all as an agent against reduced libido rather than erectile function alone [6].
What was studied
Early PT-141 research concerned erectile function: in men, including those with an inadequate response to sildenafil, the pharmacokinetics, safety and effect of intranasal and subcutaneous forms were assessed [6][7]. The program was later refocused on female hypoactive sexual desire disorder (HSDD). A dose-finding study confirmed an efficacy signal and defined an acceptable range [3]. The culmination was two identical randomized placebo-controlled phase III trials (the RECONNECT program) in premenopausal women with acquired generalized HSDD; they showed a statistically significant improvement on the co-primary endpoints (the desire domain of the FSFI, the Female Sexual Function Index, and the associated distress score on the FSDS-DAO, the Female Sexual Distress Scale) versus placebo [1]. A separate study evaluated long-term safety and tolerability with continued use [2]. On the basis of these data, the FDA (US Food and Drug Administration) in 2019 approved the brand Vyleesi for treating HSDD in premenopausal women [1][8].
Safety and limitations
The most common adverse events in the clinical trials were nausea (often a reason for discontinuation), flushing, headache and injection-site reactions [1][8]. A transient rise in blood pressure and a drop in heart rate after administration have been described, so the agent is not recommended for people with uncontrolled hypertension or cardiovascular disease [1][8]. With repeated use, focal hyperpigmentation of the skin and gums is possible, a direct consequence of the effect on the melanocortin system [8]. Historically, the intranasal form for erectile dysfunction was dropped from development precisely because of the pressure rise at higher doses, which prompted the switch to the low-dose subcutaneous form [6][8].
Level of evidence and status
For the female HSDD indication the evidence base for bremelanotide is relatively solid: it is a regulator-approved agent with two confirmatory phase III RCTs (randomized controlled trials) and a separate safety study [1][2][8]. At the same time it matters to be honest about the limits of these data. The effect in RECONNECT was statistically significant but modest in absolute size, and the benefit should be weighed against frequent nausea [1]. For other populations and indications (routine use in men, for example) quality confirmatory studies are lacking, and some of the early work had small samples [6][7]. Bremelanotide as the powder offered by research-chemical suppliers is a material for laboratory research only, not a medicine: it is not the equivalent of the approved drug in quality, dosing or control standards. Any conclusions about human use must rest on the prescription, approved product and a physician's decision.